학술논문
HRAS overexpression predicts response to Lenvatinib treatment in gastroenteropancreatic neuroendocrine tumors.
Document Type
Article
Author
Liverani, Chiara; Spadazzi, Chiara; Ibrahim, Toni; Pieri, Federica; Foca, Flavia; Calabrese, Chiara; Vita, Alessandro De; Miserocchi, Giacomo; Cocchi, Claudia; Vanni, Silvia; Ercolani, Giorgio; Cavaliere, Davide; Ranallo, Nicoletta; Chiadini, Elisa; Prisinzano, Giovanna; Severi, Stefano; Sansovini, Maddalena; Martinelli, Giovanni; Bongiovanni, Alberto; Mercatali, Laura
Source
Frontiers in Endocrinology; 1/20/2023, Vol. 14, p1-13, 13p
Subject
Language
ISSN
16642392
Abstract
Copyright of Frontiers in Endocrinology is the property of Frontiers Media S.A. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)